Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention
Related Experiment Video
Updated: Jun 16, 2025
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
1Department of Child Health, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia.
Insights
Respiratory syncytial virus (RSV) causes significant childhood respiratory illness globally. Prevention through vaccination and monoclonal antibodies offers hope for reducing its substantial health burden.
Area of Science:
- Pediatrics
- Virology
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in children worldwide.
- RSV infections present a spectrum of illness, from mild symptoms to severe bronchiolitis and pneumonia, impacting infants and high-risk children disproportionately.
- Disease severity is influenced by viral factors, strain variations, and host immune immaturity, with severe infant infections linked to long-term respiratory issues like asthma.
Purpose of the Study:
- To review the global impact, pathogenesis, diagnosis, and management of respiratory syncytial virus (RSV) infections in children.
- To highlight current preventive strategies and emerging therapeutic developments for RSV.
- To underscore the significant burden RSV places on global healthcare systems.
Main Methods:
- Literature review of RSV epidemiology, pathogenesis, clinical presentation, and diagnostic approaches.
- Analysis of current non-pharmaceutical interventions, maternal vaccination, and monoclonal antibody prophylaxis (palivizumab, nirsevimab).
- Examination of supportive care measures and the status of immunoprophylaxis and vaccine development.
Main Results:
- RSV infection leads to substantial global morbidity, particularly in infants, with seasonal variations and lasting respiratory sequelae.
- Diagnosis relies on clinical evaluation and laboratory confirmation (antigen tests, PCR).
- Effective preventive measures include non-pharmaceutical interventions, maternal vaccination, and monoclonal antibody prophylaxis, with supportive care for severe cases.
Conclusions:
- RSV remains a major global health challenge for pediatric populations.
- Advancements in immunoprophylaxis and vaccine development hold significant promise for reducing the global burden of RSV.
- Integrated preventive strategies and supportive care are crucial for managing RSV infections.
Abstract:
Respiratory syncytial virus (RSV) continues as the major cause of acute lower respiratory tract infections in children around the world, and its substantial morbidity, particularly among infants and high-risk children, poses a significant burden on healthcare systems worldwide. RSV infections occur as a spectrum, ranging from mild upper respiratory symptoms to severe bronchiolitis and pneumonia, and the number of infections shows seasonal variations in different latitudes, as well as lasting impacts, reflecting the COVID-19 pandemic. The pathogenesis of the virus involves epithelial cell invasion and/or fusion to form syncytia, along with exaggerated immune-mediated responses. Disease severity is known to depend on viral load, strain variation, and host immune immaturity. Severe RSV infection during infancy is notably linked with long-term respiratory sequelae such as recurrent wheezing and asthma. Diagnosis is based on clinical suspicion and laboratory confirmation using rapid antigen testing or nucleic acid amplification tests, namely PCR. Non-pharmaceutical interventions, maternal vaccination, and prophylaxis with monoclonal antibodies, e.g., palivizumab and nirsevimab, a newly introduced long-acting agent, are efficient protective and preventive measures. Treatment is still, for the most part, supportive in nature and focuses on oxygen supplementation, hydration, and respiratory support for patients with more severe disease courses; however, the development of immunoprophylaxis and vaccine candidates shows promise for reducing the global burden of RSV.
More Related Videos
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...